Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of different dosing schedules of Takeda tetravalent dengue vaccine in children and adolescents
2018-003978-28Phase 2
- Sponsor
- Takeda
- Start
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of dengue tetravalent vaccine, live, attenuated in dengue fever (2 arms), sponsored by Takeda. Primary endpoint: Geometric mean titers of neutralizing antibodies for each dengue virus serotype.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2018-003978-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003978-28.